Added to YB: 2026-07-01
Pitch date: 2026-06-29
CIZ.L [bullish]
Cizzle Biotechnology Holdings Plc
Author Info
No bio for this author
Company Info
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom.
Market Cap
GBP 10.2M
Pitch Price
GBP 0.03
Price Target
0.26
Dividend
N/A
EV/EBITDA
N/A
P/E
-13.77
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Cizzle Biotech - We're in the endgame now.
CIZ.L: UK diagnostics co just went commercially live in US via CLIA-accredited CIZ1B blood test for early-stage lung cancer (95% sensitivity Stage I). £10M mcap vs $5.9M contracted min royalties + 10% on US sales; even 1% penetration = $2.9M/yr. Patents in US/CA/EU, NHS LoI, 10% BIO stake. Author sees easy 10x; risks: small-cap, delays, low liquidity, adoption.
Read full article (23 min)